Transcatheter aortic valve implantation for high-risk patients with severe aortic stenosis: A systematic review

Tristan D Yan1, Christopher Cao, Julie Martens-Nielsen

  • 1Department of Cardiothoracic Surgery, The University of Sydney, Royal Prince Alfred Hospital, Sydney 2050, Australia. Tristan.Yan@unsw.edu.au

Insights

Transcatheter aortic valve implantation shows short-term efficacy for severe aortic stenosis but carries risks. Long-term outcomes remain uncertain, necessitating cautious use within clinical trials.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Medical Technology Assessment

Background:

  • Severe aortic stenosis poses significant risks for patients unsuitable for traditional surgery.
  • Transcatheter aortic valve implantation (TAVI) has emerged as an alternative treatment option.

Purpose of the Study:

  • To systematically review the safety and clinical effectiveness of TAVI in high-risk patients with severe aortic stenosis.
  • To assess the feasibility, safety, efficacy, and durability of TAVI based on available evidence.

Main Methods:

  • Conducted systematic electronic searches across 6 databases from January 2000 to March 2009.
  • Synthesized clinical effectiveness through narrative review and tabulation of results from observational studies.
  • Focused on short-term outcomes due to evidence limitations.

Main Results:

  • Procedural success rates for TAVI ranged from 74% to 100%.
  • Significant short-term adverse events were noted, including mortality (0%-25%) and major cardiovascular events (3%-35%).
  • Echocardiographic improvements in valve area and pressure gradients were observed, with no significant deterioration during follow-up.

Conclusions:

  • TAVI demonstrates short-term efficacy for severe aortic stenosis, evidenced by improved hemodynamic parameters.
  • The procedure carries a potential for serious complications, and long-term outcome data is limited.
  • Current evidence suggests TAVI should be primarily considered within the context of clinical trials.
Abstract

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...